startups, Biotech, medical

Early Stage Life Sciences Pitches—12 Firms Looking for Funding

Robert Buderi 3/25/08

(Page 2 of 2)

Children’s Hospital Boston
Carmen Barnes, instructor in surgery
carmen.barnes@childrens.harvard.edu

“We will first use our product for research use and to continue our clinical studies investigating the correlation between 2ME2 [2-Methoxyestradiol] levels and complications of prematurity. We then foresee licensing our product as companion diagnostic for complications of prematurity.”

Fission Pharmaceuticals
Charles Hoffman, professor, Boston College
hoffmacs@bc.edu

“Fission Pharmaceuticals, LLC is a drug discovery company working in the area of PDE4 and PDE4/7 inhibitors, which have tremendous potential to treat inflammatory diseases, neurological diseases, and HIV infection.”

Nemucore Medical Innovations
Tim Coleman, president and CEO
tcolemanp@earthlink.net

“Nemucore Medical Innovations…is a preclincal stage pharmaceutical company dedicated to developing, manufacturing, and marketing proprietary compounds with improved therapeutic index. NMI’s patent pending process is intended to overcome the long-term macro trend in the pharmaceutical industry to discover compounds with improved pharmaceutical activity but poor solubility.”

NKT Therapeutics
Mark Tepper, president and CEO
mtepper@nktrx.com

“NKT Therapeutics, Inc. is a biotechnology company focused on developing therapeutics based on a unique subset of immune cells called natural killer T (”NKT”) cells.”

Northeastern University and Draper Laboratory
Dale Larson, director
dlarson@draper.com

“The ‘Nanohole Array Calorimetry’ project aims to construct a breadboard device to confirm predicted improvements to calorimetry that will extend its use in the pharmaceutical and biochemistry areas…Initial market estimates are that in five years the photonic calorimeter will have a 20% market penetration worth 161 million dollars…”

P.A. Technologies
Robert Weiss, co-founder
rmw@patechllc.com

“P.A. Technologies is focused on developing novel methods for the study of signal transduction pathways. Proper cell signaling is critical for proper regulation of cell growth and division.”

Progenestem
Edward Kislauskis, co-founder
ekislauskis@hotmail.com

“Our vision is to develop enabling technology for the advancement of cell therapy in regenerative medicine.”

SkelScan
Karin Wetmore, president
kwetmore@skelscan.com

“SkelScan’s core technology is a novel method and apparatus for magnetic resonance imaging (MRI) to diagnose osteoporosis and other bone diseases, and to monitor their treatment.”

Wesfolk Corp.
Lewis Geffen, president
ljgeffen@mintz.com

“The technology platform enables several significant commercial applications in the food and beverage industries, including…a way to mimic the texture and taste of a full fat product.”

Bob is Xconomy's founder and editor in chief. You can e-mail him at bbuderi@xconomy.com, call him at 617.500.5926, or follow him on Twitter at http://twitter.com/bbuderi.